Subtype
Hepatopancreatobiliary Carcinoma
CI-CAN-00002859Explore in graph →
1,361 active trials21 approved drugs69 evidence items
- NCIt
- C214986
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002859Explore in graph →
Clinical trials
5,154 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (646)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06991907 | PD-1 Inhibitor Combined With 125I Seed Implantation for Hepatocellular Carcinoma's Extrahepatic Metastasis: Efficacy and Safety | completed | N/A | 80 | Jiangxi Provincial Cancer HospitalOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT04611165 | Concurrent Nivolumab and External Beam Radiation Therapy for Patients With Advanced HCC(Nextrah) | completed | Phase 2 | 50 | National Cancer Center, KoreaOTHER_GOV | 1 | May 22, 2025 |
| clinicaltrials |
| NCT06980792 | Surgical Approach for Adenocarcinoma of the Pancreas With Synchronous Liver Metastases | completed | — | 90 | Azienda Ospedaliero-Universitaria di ModenaOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT02764801 | Contrast-enhanced Ultrasound Evaluation of Chemoembolization | completed | Phase 3 | 131 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT05750030 | FMT in IT-refractory HCC - FAB-HCC Pilot Study | completed | Phase 2 | 12 | Medical University of ViennaOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT01754987 | A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective | completed | Phase 1 / Phase 2 | 5 | Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT04581343 | A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (PC) Patients(PanCAN-SR1) | completed | Phase 1 | 10 | Pancreatic Cancer Action NetworkOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT02632448 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | completed | Phase 1 / Phase 2 | 229 | Esperas Pharma Inc.OTHER | 4 | May 2, 2025 | clinicaltrials |
| NCT03045497 | Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Liver Cancer Receiving Transarterial Chemoembolization With Drug Eluting Beads | completed | Phase 1 | 15 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 0 | May 2, 2025 | clinicaltrials |
| NCT05239169 | Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer | completed | Phase 2 | 40 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT02517268 | Accelerated Recovery Pathway for Discharge After Surgery in Patients With Pancreatic Cancer(WARP) | completed | N/A | 98 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT02896907 | Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery | completed | Early Phase 1 | 8 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT05383352 | A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas(SIRACUSA) | completed | Phase 1 | 177 | IpsenINDUSTRY | 7 | Apr 30, 2025 | clinicaltrials |
| NCT01349075 | TheraSphere for the Treatment of Unresectable Hepatocellular Carcinoma | completed | — | 474 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT04720430 | Blood Sample Collection for Experimental Blood Test to Track Liver Cancer | completed | — | 7 | Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT06947395 | Clinical Validation of a Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer (VERIFI)(VERIFI) | completed | — | 386 | Immunovia, Inc.INDUSTRY | 1 | Apr 27, 2025 | clinicaltrials |
| NCT03783871 | NeuWave Microwave Ablation HCC China Study(NW) | completed | N/A | 135 | Ethicon, Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06092112 | A Clinical Trial for the Safety and Efficacy of CD-801 in Patients With Advanced Hepatocellular Carcinoma | completed | Early Phase 1 | 2 | Shanghai Changzheng HospitalOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT06544005 | Implication of Long Non-coding RNA HOTTIP Haplotype on Liver Cancer Metastasis | completed | — | 198 | Ain Shams UniversityOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT02230176 | Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II(OCCLURANDOM) | completed | Phase 2 | 84 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT03507140 | Microbiota Study in Liver Transplanted Patients(BIM-LT) | completed | — | 64 | University Hospital, GrenobleOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT02234986 | A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma | completed | Phase 2 | 35 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | Apr 18, 2025 | clinicaltrials |
| NCT03861702 | Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma: | completed | Phase 2 | 28 | Nelson YeeOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT06933576 | Contribution of the EyeMAX™ 11Fr (Micro-Tech) Digital Single-Operator Cholangioscope With a Wide Working Channel(EyeMAX-CREGG) | completed | — | 28 | Clinique Paris-BercyOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT02990481 | A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors | completed | Phase 1 | 38 | Toray Industries, IncINDUSTRY | 2 | Apr 16, 2025 | clinicaltrials |
| NCT05673811 | Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer(VIRAGE) | completed | Phase 2 | 112 | Theriva Biologics SLINDUSTRY | 2 | Apr 16, 2025 | clinicaltrials |
| NCT04000737 | YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 62 | Yiviva Inc.INDUSTRY | 4 | Apr 13, 2025 | clinicaltrials |
| NCT03934606 | Evaluating an Alternative Clinical Genetics Cancer Care Deliver Model | completed | — | 1,488 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT06916546 | SIRT or TACE Plus Lenvatinib and PD-(L)1 Inhibitor in High Burden HCC | completed | — | 238 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT04229004 | A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer | completed | Phase 3 | 502 | Pancreatic Cancer Action NetworkOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT04602026 | The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer(RIOT) | completed | N/A | 66 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT04316182 | Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION)(ACTION) | completed | Phase 2 | 24 | Fundacion Clinic per a la Recerca BiomédicaOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT04436679 | INTER-Regional COHORTE of Long Term Pancreatic Cancer Survivors(CaPaLong) | completed | — | 342 | University Hospital, LilleOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06899763 | Single-Cell Profiling of Liver-infiltrating Immune Cells of Patients with NASH- and Virus-related HCC: Implications for Immunotherapy(1003rcr2022_72) | completed | — | 6 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT02052778 | A Study of TAS-120 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 407 | Taiho Oncology, Inc.INDUSTRY | 13 | Mar 27, 2025 | clinicaltrials |
| NCT06416683 | Atezolizumab and Bevacizumab Combination Recommended in a Multidisciplinary Consultation Meeting in Caen for Hepatocellular Carcinoma (ABCHCaen)(ABCHCaen) | completed | — | 109 | University Hospital, CaenOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT04137289 | A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer | completed | Phase 1 | 110 | Boehringer IngelheimINDUSTRY | 8 | Mar 25, 2025 | clinicaltrials |
| NCT03195699 | Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers | completed | Phase 1 | 64 | Tvardi Therapeutics, IncorporatedINDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06503250 | A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization | completed | — | 113 | Hoffmann-La RocheINDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06888401 | Clinico-demographic Profile of the Patient With Pancreaticobiliary Malignancy Undergoing ERCP in a Tertiary Care Center of Nepal | completed | — | 597 | Kathmandu University School of Medical SciencesOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04484636 | PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)(PLATON) | completed | N/A | 400 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT05340569 | Diagnostic Value of DWI-MRI for Detection of Peritoneal Metastases in High-risk Pancreatic Ductal Adenocarcinoma.(DWI-PDAC) | completed | N/A | 40 | Laval UniversityOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT04668781 | Improvement of Care of Patients Undergoing Pancreaticoduodenectomy | completed | N/A | 92 | Helsinki University Central HospitalOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT05250895 | BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy | completed | Early Phase 1 | 9 | Emory UniversityOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04401800 | Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma | completed | Phase 2 | 64 | BeiGeneINDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT03397654 | Study of Pembrolizumab Following TACE in Primary Liver Carcinoma(PETAL) | completed | Phase 1 / Phase 2 | 26 | Imperial College LondonOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT04710641 | Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone(OUTREACH2) | completed | Phase 2 | 8 | Mina Alpha LimitedINDUSTRY | 2 | Mar 6, 2025 | clinicaltrials |
| NCT05233098 | TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA. | completed | — | 6 | Boston Scientific CorporationINDUSTRY | 1 | Mar 6, 2025 | clinicaltrials |
Data updated 23 days agoSource updated May 28, 2025source: clinicaltrials